Endo to buy Par Pharma for $8B to bulk up in injectables

Endo ($ENDP) is acquiring Par Pharmaceutical for $8 billion. It adds about 100 products from Par, such as generic injectables worth $1.3 billion in 2014 sales. Injectables are tougher to manufacture than pills, which means the competition is lower, garnering higher profitability. "This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A," Endo CEO Rajiv De Silva said. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.